Drawing for SIERRA ONCOLOGY

USPTO serial 90848313

SIERRA ONCOLOGY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
VERHOSEK, WILLIAM T
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SIERRA ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher M. Hanes

Christopher M. Hanes GSK410 Blackwell StreetLegal Brand ProtectionDurham, NC 27701

Goods and services

ClassDescriptionStatusFirst use
005Biological and chemical preparations for the treatment of cancer; pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and disorders; pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation; pharmaceutical preparations for use in the prevention and treatment of dermatology, oncology, hematology and for gastroenterological disorders but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantationACTIVE—
042Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines; medical research; pharmaceutical research and development services; medical research services in the field of cancer; research and development of biological and chemical preparations for the treatment of blood diseases, bone and bone marrow diseases, and cancer; research and development of pharmaceutical products, preparations and compounds for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development of pharmaceutical preparations for use in dermatology, oncology, hematology, and for gastroenterological disorders; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials regarding pharmaceutical preparations and drugs in the field of blood diseases, and cancers; DNA screening and analysis services for scientific research purposesACTIVE—
044Medical services; medical services for the treatment of cancer; medical analysis services for the diagnosis and treatment of patients and persons; medical analysis services for the diagnosis of cancer; providing cancer screening services; providing a website via a global computer network featuring information in the fields of health and health information regarding cancer, cancer treatment, recovery and survival; medical evaluation and diagnosis of cancer; medical analysis for cancer diagnosis and prognosis based on DNA and RNA screening; medical services for the diagnosis of conditions of the human body; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of dermatology, oncology, hematology, and for gastroenterological disorders; providing medical information, consultancy and advisory services; providing links to the websites of others featuring information about the diagnosis and treatment of cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 4, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 4, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 2, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 31, 2023EX1GSOU EXTENSION 1 GRANTED—
Jul 31, 2023EXT1SOU EXTENSION 1 FILED—
Jul 31, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 8, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 31, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 6, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 6, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 16, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 31, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 21, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 20, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 20, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 12, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 12, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 12, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 21, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 20, 2022DOCKASSIGNED TO EXAMINER—
Sep 24, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 29, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance